RxDoctor Payments Data

Martha Todd, NP

Family · Hendersonville, NCNPI 1407800139

Payments from drug & device makers

$8,987in general payments, 2019–2025

Across 443 payments — averaging $20.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$811
  • AstraZeneca$772
  • Lilly USA, LLC$657
  • Amgen$648
  • GSK$490
  • plus $5K from 37 others

What the payments were for

  • Food & beverage$8,72297%
  • Education$2653%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,987 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$81,378
Medicare patients
218
Services billed
1,265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban144$124,150
Humira PenAdalimumab14$102,326
EliquisApixaban74$63,514
JardianceEmpagliflozin50$50,370
RybelsusSemaglutide18$31,748
OzempicSemaglutide25$26,945
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$18,957
MounjaroTirzepatide15$17,689
FarxigaDapagliflozin Propanediol16$13,634
TrulicityDulaglutide11$12,680
LinzessLinaclotide20$10,932
MyrbetriqMirabegron17$9,899
Tresiba Flextouch U-100Insulin Degludec22$9,015
Breo ElliptaFluticasone/Vilanterol23$7,339
TrulancePlecanatide13$7,044

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$405$124,150144 claims
PfizerEliquis, Prempro$202$66,37687 claims
Novo NordiskRybelsus, Ozempic$811$58,69343 claims
Boehringer IngelheimJardiance$250$50,37050 claims
Lilly USA, LLCMounjaro, Trulicity$657$30,36826 claims
GSKTrelegy Ellipta, Breo Ellipta$490$26,29651 claims
AstraZenecaFarxiga, Symbicort$772$17,29727 claims
AbbVieLinzess, Synthroid$1,071$15,65268 claims
Astellas Pharma US IncMyrbetriq$389$9,89917 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$404$7,04413 claims
MerckSteglatro$41$4,28112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Hendersonville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →